U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Pfizer CEO Albert Bourla plans to meet key executives of activist hedge fund Starboard Value next week, the Financial Times ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

Pfizer (NYSE: PFE) was a stock on the move Wednesday, and not because of any news generated by the healthcare company.

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend on the ...

With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...

Pfizer CEO Albert Bourla reportedly is planning to meet with Starboard Value after the activist investor took a $1 billion ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...